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Proximal Left Anterior Descending Artery Treatment Using a
Bioresorbable Polymer Coating Sirolimus-Eluting Stent: Real-World
Outcomes From the Multicenter Prospective e-Ultimaster Registry
Pablo Codner, MD;* Majdi Saada, MD;* Orazbek Sakhov, MD; Jawed Polad, MD; Fazila Tun-Nesa Malik, MD; Shahzad Munir, MD;
Mamas Mamas, MD; Jim Crowley, MD; Jacques Monsegu, MD; Luis Perez, MD; Sasko Kedev, MD, PhD; David Austin, MD;
Ariel Roguin, MD, PhD; on behalf of e-Ultimaster investigators
Background-—Guidelines recommend heart team discussion and coronary artery bypass graft consideration in patients with proximal
left anterior descending (LAD) artery stenosis. Evidence suggests that outcomes of proximal LAD angioplasty might not differ from
treatment of nonproximal LAD locations. We aim to determine clinical outcomes of patients undergoing percutaneous coronary
intervention in the proximal LAD segment in comparison with nonproximal LAD angioplasty, using a thin-strut drug-eluting stent.
Methods and Results-—In this analysis of the e-Ultimaster registry, patients undergoing angioplasty in the proximal LAD territory
were compared with those treated in nonproximal LAD locations. Multivariate analysis and propensity score were used to adjust for
differences among the groups. The primary outcome was target lesion failure: a composite of cardiac death, target-lesion–related
myocardial infarction, and/or clinically driven target lesion revascularization at 1-year follow-up. Of the 17 805 patients (mean age,
64.211; 76% male), 5452 (30.6%) underwent proximal LAD and 12 353 (69.4%) nonproximal LAD percutaneous coronary
intervention. Patients in the proximal LAD group had more multivessel disease (48.7% versus 43.5%; P<0.001) and 2-fold more
bifurcations lesions (18.8% versus 9.2%; P<0.0001). After propensity-weighted adjustment, target lesion failure did not differ
between the groups (3.3% versus 2.9%; P=0.17 for proximal LAD versus nonproximal LAD angioplasty, respectively). In multivariate
analysis, proximal LAD treatment was not an independent predictor of target lesion failure (odds ratio, 1.07; 95% CI, 0.88–1.31;
P=0.48).
Conclusions-—At 1-year follow-up, patients had similar clinical outcomes independent of stenting location, questioning whether
proximal LAD treatment should be regarded differently from stenting in any other coronary artery territory. ( J Am Heart Assoc.
2019;8:e013786. DOI: 10.1161/JAHA.119.013786.)
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P roximal left anterior descending (LAD) coronary arterydisease is considered as a high-risk feature in
interventional cardiology attributable to the large area of
myocardium it supplies. Patients with stable coronary artery
disease and isolated proximal LAD disease have similar
survival rates whether treated with coronary artery
bypass graft (CABG) or percutaneous coronary intervention
(PCI).1–3
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Current revascularization guidelines recommend a “heart
team” discussion in patients with stable coronary artery
disease and proximal LAD disease and confer a class I
indication level of evidence A to both, percutaneous and
surgical, treatment strategies.4 Yet, this is not the case when
isolated lesions in the right coronary artery or left circumflex
are planned for treatment.
Whether PCI of the proximal LAD segment is associated
with higher rates of adverse events in comparison with
nonproximal LAD PCI has been of interest. Several subgroup
analyses of randomized and registry trials found no major
differences in mortality or in the composite rate of major
adverse cardiac events (MACE).5–8 We aimed to compare
outcomes of a large cohort of patients enrolled in the
e-Ultimaster prospective and multinational registry study
undergoing drug-eluting stent (DES) implantation and strati-
fied according to lesion location within or outside the proximal
LAD artery.9
Methods
Study Design
The large e-Ultimaster is an all-comer, single-arm, prospective,
and multicenter registry. The study was conducted worldwide
across Europe, Asia, South America, and Africa to further
evaluate the safety and performance of the Ultimaster DES
system (Terumo Corporation, Tokyo, Japan) in an all-comer
clinical setting.9
Inclusion and exclusion criteria were described previously.9
Briefly, patients with coronary artery disease (reference vessel
diameters between 2.5 and 3.5 mm) eligible for PCI using
DES according to local hospital practice and who were treated
using the Ultimaster stent were enrolled in the registry. Local
institutional review board approval was obtained at each
institution while subjects included in the registry were waived
to provide informed consent.
Inclusion Criteria for the Current Analysis
The present study analyzed clinical outcomes of patients
enrolled in the e-Ultimaster registry divided according to
whether stents were implanted in a proximal LAD versus a
nonproximal LAD segment. In cases where stents were
implanted in the proximal LAD as well as in another location,
they were grouped into the proximal LAD group. Patients with
left main segment involvement and treatment and those with
previous CABG surgery were excluded. All other patients from
the e-Ultimaster registry with a follow-up at 3 months and
1 year were included.
In this interim analysis, proximal LAD was defined accord-
ing to the CASS (Coronary Artery Surgery Study) classifica-
tion11: end of left main to the first large septal or first
diagonal, whichever is more proximal. The current interim
analysis assessed data of 19 842 patients enrolled between
October 2014 and May 2017 who had complete 3-month and
1-year follow-up data or had died on the date of census (May
31, 2018; Figure 1).
Renal impairment was defined as estimated glomerular
filtration rate <60 mL/min/1.73 m2. Lesion complexity was
defined by the American College of Cardiology/American
Heart Association classification.12
Study Device
The Ultimaster coronary stent system is a new-generation,
open-cell, cobalt-chromium, thin-strut (80-lm) sirolimus-
eluting stent with an abluminal bioresorbable polymer coating
(poly-D,L-lactic acid polycaprolactone).10 Sirolimus is released
over a 3- to 4-month period, after which the polymer coating
is fully degraded.
Outcomes and Definitions
The primary outcome was target lesion failure (TLF) defined as
a composite of cardiac death, target vessel–related myocar-
dial infarction (MI), and for clinically driven target lesion
revascularization (TLR) at 1-year follow-up.
Secondary outcomes included any death, cardiac death,
MI, rate of TLR, rate of target vessel revascularization (TVR),
target vessel failure (a composite of cardiac death, target-
vessel–related MI, and TVR), and major vascular and bleeding
complications. Stent thrombosis was defined according to the
Academic Research Consortium definitions at 3-month and 1-
year follow-up. Patient-oriented composite end point (POCE)
was defined as a composite of any death, any MI, and any
coronary revascularization. All end-point–related serious
adverse events were reviewed and adjudicated by an
independent clinical event committee.
Clinical Perspective
What Is New?
• From the analysis of this large all-comer stent registry,
clinical outcomes of patients with coronary artery disease in
the proximal left anterior descending segment did not differ
from those with coronary obstruction elsewhere in the
coronary tree.
What Are the Clinical Implications?
• The study contributes to the growing evidence that the
proximal left anterior descending segment should not be
considered differently than other coronary arteries or
segments at the time of with current available techniques,
devices and medications.
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The data that support the findings of this study are
available from the corresponding author upon reasonable
request.
Statistical Analysis
Baseline characteristics were reported as mean and SDs for
continuous variables and number and percentages for categor-
ical variables. Statistical differences between baseline charac-
teristics were reported using a t test for continuous variables
and chi-squared test for categorical variables while the
outcomes of interest were reported at 3 months and 1 year.
To reduce the effect of baseline differences between the 2
groups, a propensity-score analysis was performed using
separate models for lesion location. Propensity scores were
calculated using a logistic regression model, with the subgroup
(proximal LAD or nonproximal LAD) as outcome and the
variables which needed to be matched for as independent
variables. The probability of belonging to 1 of the 2 groups was
used as a propensity score. Variables to be entered into the
model were predefined based on any possible impact on the
outcomes and included: age, sex, body mass index, smoking,
hypertension, hypercholesterolemia, history of MI, previous
PCI, ST-segment–elevation myocardial infarction, multivessel
disease, number of lesions treated, number of stents implanted,
length of implanted stents, type B2 and C lesions, bifurcation,
moderate to severe calcification, ostial lesions, long lesions
(≥25 mm), small vessels (1 stent ≤2.75 mm), radial access,
postdilatation, and thrombus aspiration. The inverse probability
of treatment weights methodology was used to perform a
matched analysis. This methodology uses the inverse of the
propensity score of its own subgroup (ie, the probability of the
subject of belonging to the subgroup it is in) as a weight that can
be used in the analyses. Using these weights, analyses were
balanced for the covariates in the logistic regressionmodel. The
balance after matching can be tested by calculating weighted
standardized difference for the inverse probability of treatment
weights analysis using the calculated weights. Generally,
standardized difference for all variables below 0.20 are
considered well balanced, whereas standardized difference
for all variables below 0.10 can be considered extremely well
balanced (Figure S1). Weighted chi-square tests were used for
binary or categorical data; weighted Wilcoxon rank-sum tests
were used for continuous data.
Multivariate analyses on the proximal LAD subgroups
included logistic regression models to assess the odds ratio of
events. For primary outcome target lesion failure, a stepwise
selected model was used, where all variables are entered 1 by
1 if their P value is <0.25 (“entry P value”) and retains the
variables in next steps when the P value remains below 0.15
(“stay P value”). This gives a model with only a set of
important, predictive variables and also avoiding multi-
collinearity. The variables entered were age, sex, body mass
index, diabetes mellitus, hypertension, hypercholesterolemia,
Figure 1. Study flow chart and primary outcome results. CABG indicates coronary artery bypass graft;
LAD, left anterior descending; d, days; mo, months; yr, year.
DOI: 10.1161/JAHA.119.013786 Journal of the American Heart Association 3
Left Anterior Descending Angioplasty Outcomes Codner et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on April 28, 2020
smoking, previous MI, previous PCI, renal impairment, acute
coronary syndrome, multivessel disease, number of lesions
identified, number of lesions treated, number of stents
implanted, length of stents implanted, in-stent restenosis,
chronic total occlusion, bifurcation, long lesions, small
vessels, moderate-to-severe calcification, lesions type accord-
ing to the American College of Cardiology/American Heart
Association classification, and radial access. Proximal LAD
lesion, age, and sex were forced into the logistic regression
model.
P<0.05 was considered significant. Statistical analyses
were performed using SAS software (version 9.4; SAS
Institute Inc., Cary, NC).
Results
Study Patients
The e-Ultimaster registry recruited 37 000 patients in 413 sites
over 50 countries. Enrollment ended in May 2018. The current
Table 1. Baseline Patients Characteristics
Unadjusted Propensity Weighted
Proximal LAD
n=5452 (%)
Nonproximal LAD
n=12 353 (%) P Value
Proximal LAD
n=5452 (%)
Nonproximal LAD
n=12 353 (%) P Value
Age, y 64.111.3 64.311.0 0.28 64.111.3 64.111.1 0.99
Male sex 4180/5452 (76.7) 9400/12 353 (76.1) 0.41 4156/5420 (76.2) 9333/12 353 (76.2) 0.99
Current smoker 1117/5050 (22.1) 2895/11 446 (25.3) <0.001 1177/5055 (23.3) 2668/11 418 (23.4) 0.92
Diabetes mellitus 1457/5452 (26.7) 3400/12 353 (27.5) 0.27 1475/5452 (27.1) 3295/12 352 (26.7) 0.59
Hypertension 3148/5195 (60.6) 7532/11 815 (63.8) <0.001 3196/5194 (61.5) 7242/11 791 (61.4) 0.89
Hypercholesterolemia 2755/5204 (52.9) 6680/11 777 (56.7) <0.001 2797/5204 (53.7) 6337/11 747 (53.9) 0.81
Renal impairment 387/5450 (7.1) 836/12 349 (6.8) 0.42 387/5450 (7.1) 831/12 349 (6.7) 0.35
Previous MI 900/5261 (17.1) 2499/11 992 (20.8) <0.001 950/5264 (18.0) 2152/11 987 (18.0) 0.89
Previous PCI 997/5260 (19.0) 3101/12 001 (25.8) <0.001 1087/5263 (20.6) 2464/11 988 (20.6) 0.87
ACS 3113/5446 (57.2) 7025/12 345 (56.9) 0.75 3125/5446 (57.4) 7121/12 344 (57.7) 0.70
STEMI 1201/5446 (22.1) 2567/12 345 (20.8) 0.06 1211/5446 (22.2) 2743/12 344 (22.2) 0.99
Multivessel disease 2656/5452 (48.7) 5372/12 352 (43.5) <0.001 2546/5452 (46.7) 5768/12 353 (46.7) 0.99
Values are meanSD or percentage (number). ACS indicates acute coronary syndrome; LAD, left anterior descending artery; MI, myocardial infarction; PCI, percutaneous coronary
intervention; STEMI, ST-segment–elevation myocardial infarction.
Table 2. Baseline Lesion and Procedural Characteristics
Unadjusted Propensity Weighted
Proximal LAD
n=5452 (%)
Nonproximal LAD
n=12 353 (%) P Value
Proximal LAD
n=5452 (%)
Nonproximal LAD
n=12 353 (%)
P
Value
No. of lesions detected, n 1.921.06 1.791.05 <0.001 1.871.04 1.871.08 0.94
No. of lesions treated, n 1.440.70 1.290.57 <0.001 1.380.64 1.380.67 0.99
Type C lesions (ACC/AHA classification) 1407/4569 (30.8) 2868/10 321 (27.8) <0.001 1358/4529 (30.0) 3076/10 412 (29.5) 0.59
Ostial lesion 472/5420 (8.7) 625/12 241 (5.1) <0.001 382/5417 (7.1) 866/12 263 (7.1) 0.99
Moderate-to-severe calcification 1113/5420 (20.5) 2102/12 241 (17.2) <0.001 1049/5417 (19.4) 2376/12 263 (19.4) 0.98
Bifurcation 1020/5420 (18.8) 1130/12 241 (9.2) <0.001 785/5417 (14.5) 1778/12 263 (14.5) 0.98
Long lesion (≥25 mm) 2618/5436 (48.2) 5020/12 305 (40.8) <0.001 2492/5436 (45.8) 5647/12 305 (44.9) 0.96
Small vessels (≤2.75 mm) 2124/5436 (39.1) 5770/12 305 (46.9) <0.001 2199/5436 (40.5) 4982/12 305 (40.5) 0.97
Radial access 4373/5356 (81.7) 10 269/12 118 (84.7) <0.001 4432/5363 (82.6) 10 041/12 095 (83.0) 0.53
No. of implanted study stents, n 1.590.95 1.390.75 <0.001 1.510.86 1.510.88 0.99
Total length of implanted study stents, mm 35.824.1 30.619.8 <0.001 33.922.1 33.922.9 0.99
Postdilatation 2794/5452 (51.3) 5181/12 352 (41.9) <0.001 2624/5452 (48.1) 5945/12 353 (48.1) 0.99
Values are meanSD or percentage (number). ACC/AHA indicates American College of Cardiology/American Heart Association; LAD, left anterior descending artery.
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interim analysis includes 19 842 patients with complete 1-year
follow-up data by May 2018, of which 2037 were excluded
because of previous CABG and/or left main disease involve-
ment. Patients (n=17 805) treated with stent implantation
within the proximal LAD segment (N=5452) were compared
with those treated in a nonproximal LAD (N=12 353) territory.
To adjust for differences in baseline characteristics, a propen-
sity-score analysis was done (see flowchart, Figure 1).
Baseline Demographics
Patients’ (N=17 805; 23.7% women) mean age was
64.211.1. Baseline characteristics (unadjusted and
propensity-score adjusted) comparing the 2 groups are
presented in Table 1. Patients in the proximal LAD group
had lower-incidence hypertension, hypercholesterolemia,
current smoking, and previous MI than their counterparts
(Table 1). Stable angina was the reason for PCI in 1885
(34.6%) patients in the proximal LAD versus 4215 (34.1%) in
the nonproximal group (P=0.55).
Procedural and Lesion Characteristics
Procedural details and angiographic information (unadjusted
and propensity adjusted) are presented in Table 2. Multives-
sel disease incidence was higher in patients treated in the
proximal LAD segment (48.7% versus 43.5%; P<0.001) and
had 2-fold more bifurcation than those treated in other
locations (18.8% versus 9.2%; P<0.0001). Rates of long
(>25 mm) and moderate-to-severe calcified lesions were
higher in the proximal LAD group, and lesion complexity
(according to the American College of Cardiology/American
Figure 2. Subgroup analysis (logistic regression) showing propensity-adjusted relative risk (RR) with 95% CI. ACS indicates acute coronary
syndrome; IPTW, inverse probability of treatment weights; proxLAD, proximal left anterior descending; RR, relative risk.
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Heart Association classification)12 was, in general, more
severe in these patients as well (Table 2). Patients in the
proximal LAD group had, on average, more lesions treated and
more stents implanted and hence an overall longer stent
length. The complete distribution of the lesions in both groups
is detailed in Table S1.
Clinical Outcomes
All patients included in the current analysis completed
3-month and 1-year follow-up. Table S2 details the nonad-
justed event rates. After propensity weighing (Figure S1), the
primary end point of TLF was similar among treatment groups
(76 [1.4%] versus 179 [1.5%]; P=0.76 and 177 [3.3%] versus
354 [2.9%]; P=0.17, for proximal LAD versus nonproximal LAD
at 3-month and 1-year follow up, respectively).
Subgroup analysis (logistic regression) showing propensity-
adjusted relative risk with 95% CI are presented in Figure 2.
Separate subanalyses and event rates of proximal LAD lesions
with 1-, 2-, and 3-vessel disease and for diabetes mellitus
appear in Tables S3 and S4 and Figures S2 and S3. Diabetes
mellitus or multivessel disease were not a significant effect
modifier for the risk of TLF between proximal LAD and
nonproximal LAD group (no significant interaction effect).
Propensity-weighted–adjusted rates of all-cause mortality,
cardiac death, and any MI and the composite end points of
target vessel failure and patient-oriented composite end point
were not different within studied groups at 3-month or 1-year
follow-up (Table 3). Propensity-weighted target lesion and
vessel revascularizations were similar at 3-month follow-up
(TLR [0.46% versus 0.49%; P=0.83] and TVR [0.6% versus
0.73%; P=0.32]), but higher at 1-year follow-up in the proximal
LAD group (TLR [1.8% versus 1.3%; P=0.008] and TVR [2.4%
versus 1.9%; P=0.06]). Relief from angina symptoms was
similar at 3 months (angina-free rate, 91.8% versus 91.6%;
P=0.68) and at 1 year (angina-free rate, 92.1% versus 91.3%;
P=0.12) in proximal LAD compared with nonproximal-LAD–
treated patients, respectively. Definite and probable stent
thrombosis rates at 1 year were low and similar (0.67% versus
0.64%; P=0.77). Both groups received similar duration of dual
antiplatelet therapy at discharge (97.9% versus 97.5%;
P=0.15) and at 3 months (94.6% versus 94.7%; P=0.83), with
slightly higher dual antiplatelet therapy at 1-year follow-up in
the proximal LAD group (67.6% versus 65.9%; P=0.03).
Multivariate Analysis
We also performed a multivariate logistic regression analysis;
proximal LAD stenting was not identified as an independent
predictor for the primary outcome measure of TLF (odds ratio,
1.07; 95% CI, 0.88–1.31; P=0.48; Table 4). The following
variables were predictors of TLF: age, diabetes mellitus, renal
impairment, previous PCI, acute coronary syndrome, and
angiographic complexity of the lesion.
Table 3. Propensity-Adjusted Clinical Outcomes
3-month 1-year
Proximal LAD
n=5452 (%)
Nonproximal LAD
n=12 353 (%) P Value
Proximal LAD
n=5452 (%)
Nonproximal LAD
n=12 353 (%) P Value
All-cause death 55/5452 (1.0) 106/12 353 (0.9) 0.27 117/5452 (2.1) 246/12 353 (2.0) 0.53
Cardiac death 45/5452 (0.8) 76/12 353 (0.6) 0.10 73/5452 (1.3) 147/12 353 (1.2) 0.44
Any MI 26/5452 (0.5) 96/12 353 (0.8) 0.03 51/5452 (0.9) 145/12 353 (1.2) 0.16
Target-vessel MI 24/5452 (0.4) 81/12 353 (0.7) 0.08 40/5452 (0.7) 117/12 353 (1.0) 0.16
All TLR 27/5452 (0.5) 61/12 353 (0.5) 0.99 101/5452 (1.9) 167/12 353 (1.4) 0.01
Clinically driven TLR 25/5452 (0.5) 60/12 353 (0.5) 0.83 97/5452 (1.8) 158/12 353 (1.3) 0.008
All TVR 35/5452 (0.6) 93/12 353 (0.8) 0.41 134/5452 (2.5) 250/12 353 (2.0) 0.06
Clinically driven TVR 33/5452 (0.6) 91/12 353 (0.7) 0.32 128/5452 (2.4) 237/12 353 (1.9) 0.06
TLF 76/5452 (1.4) 179/12 353 (1.5) 0.76 177/5452 (3.3) 354/12 353 (2.9) 0.17
TVF 82/5452 (1.5) 201/12 353 (1.6) 0.55 204/5452 (3.7) 419/12 353 (3.4) 0.25
POCE 124/5452 (2.3) 304/12 353 (2.5) 0.47 321/5452 (5.9) 717/12 353 (5.8) 0.82
Definite or probable ST 28/5452 (0.5) 69/12 353 (0.6) 0.71 37/5452 (0.7) 79/12 353 (0.6) 0.77
Bleeding (BARC 1–5) 68/5452 (1.3) 164/12 353 (1.3) 0.67 120/5452 (2.2) 276/12 353 (2.2) 0.89
Values are percentage (number). BARC indicates Bleeding Academic Research Consortium; LAD, left anterior descending artery; MI, myocardial infarction; POCE, patient-oriented
composite end point, a composite of all-cause death, any MI, and any coronary revascularization; TLF, target lesion failure, a composite of cardiac death, target-vessel MI, and clinically
driven TLR; TLR, target lesion revascularization; TV, target vessel; TVF, target vessel failure, a composite of cardiac death, target-vessel MI, and clinically driven TVR; TVR, target vessel
revascularization; ST, stent thrombosis.
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Discussion
In this large, real-world analysis of all-comer stent practice
from a prospective, multicenter large registry, we report
comparable clinical and procedural outcomes in patients
treated for proximal LAD lesions compared with nonprox-
imal LAD lesion at both 3-month and 1-year follow-up. The
dogma that patients with proximal LAD lesions treated with
PCI are thought to have greater risks of future cardiac
events compared with patients with lesions in other
coronary segments was found not to be true in our large
study.
The optimal treatment of proximal LAD stenosis remains a
matter of debate. Data derived from the current study and
other contemporary data question whether the proximal LAD
segment should be considered and treated differently than
other proximal lesions elsewhere in the coronary vasculature
in contemporary coronary revascularization guidelines.5–8
The LAD supplies a large portion of the left ventricular
myocardium; hence, compromise of this artery can have
adverse consequences for left ventricular function and
prognosis. Randomized controlled trials have shown similar
mortality and MACE after treatment of single proximal LAD
lesions with a DES or CABG.13,14
The present registry includes only stented patients and
therefore has an inherited selection bias. It does not contain
any comparison with CABG patients. The choice of revascu-
larization was done before entering into the registry. It is
difficult to know why those patients were referred to surgery
and how they would have fared if they underwent PCI. The 1-
year repeat revascularization was higher in the proximal LAD
group (TLR 1.8% versus 1.3%; P=0.008 and TVR 2.4% versus
1.9%; P=0.06). The incidence is small, but may suggest
another potential reason why CABG may be preferred and
emphasizing the need for such a study. Therefore, while the
point of similar outcomes of proximal LAD patients to those
with other lesions is well taken, it is not the same as the
comparison with those who were referred to surgery.
Obviously, if that was available, there will be a host of
selection biases that will be difficult to account for as well.
In the SORT OUT (Scandinavian Organization for Random-
ized Trials With Clinical Outcome) II trial,8 there was a 12%
TLR rate 10 years after treatment of a proximal LAD lesion
with first-generation DES. This result is fairly similar to the one
expected after CABG using the left internal mammary artery
to the LAD. The reported long-term patency rates for this
bypass graft vary slightly according to whether patients with
multivessel disease are also included (85–90% patency
rates)14–16 or whether patients have only single proximal
LAD lesions (89–100% patency rates).17,18 Contemporary
studies have reported similar outcomes in the medium and
longer term in proximal LAD lesions compared with other
lesions treated with PCI. The NOBORI-2 trial found no
differences in outcomes between patients who underwent
PCI of the proximal LAD (N=834) and those treated in a
nonproximal LAD territory (N=2203), using the NOBORI
Bioliomus A9 DES.5 In another study, Roguin et al analyzed
4-year outcomes of 8709 patients undergoing PCI with either
the Endeavor zotarolimus-eluting stent or the Cypher sirolimus-
eluting stent enrolled in the PROTECT (Prophylaxis for
Thromboembolism in Critical Care Trial) trial. Patients were
stratified according to lesion location within or outside the
proximal LAD. At 4-year follow-up, mortality rates, target vessel
failure, stent thrombosis, and MACE were the same, although
patients in the proximal LAD group had higher rates of MI.6
Ten-year clinical outcomes expressed as all-cause mortal-
ity and MACE were determined for 1479 patients with a single
non-left-main coronary stenosis treated with a first-generation
DES in the SORT OUT II trial.8 Patients treated with a DES in
the proximal LAD were found to have similar, if not better,
long-term clinical outcomes compared with patients stented
in other coronary artery segments. Follow-up was 99.3%
Table 4. Multivariate Logistic Regression: Odds Ratio for Risk
of 1-Year Target Lesion Failure
Odds Ratio 95% CI P Value
Proximal LAD, yes 1.07 0.88–1.31 0.48
Age, +10 y 1.25 1.15–1.37 <0.001
Male sex 1.09 0.88–1.35 0.42
Body mass index, +1 kg/m² 0.98 0.961–1.004 0.12
Diabetes mellitus, yes 1.71 1.42–2.06 <0.001
Hypercholesterolemia, yes 0.84 0.70–1.01 0.07
Renal impairment, yes 1.81 1.40–2.34 <0.001
Previous PCI, yes 1.57 1.29–1.91 <0.001
Acute coronary
syndrome, yes
1.39 1.15–1.67 0.001
Right coronary artery
treated, yes
0.81 0.65–0.99 0.04
Graft treated, yes 3.75 0.81–17.4 0.09
No. of lesions identified, +1 1.23 1.13–1.34 <0.001
No. of lesions treated, +1 0.88 0.75–1.03 0.11
No. of implanted stents, +1 1.39 1.14–1.69 0.001
Length of implanted
stent, +1 mm
0.99 0.985–1.001 0.08
Bifurcation, yes 1.56 1.24–1.96 <0.001
Type A lesion
(ACC/AHA classification), yes
0.57 0.37–0.88 0.01
Type C lesion
(ACC/AHA classification), yes
1.31 1.07–1.61 0.009
ACC/AHA indicates American College of Cardiology/American Heart Association; LAD,
left anterior descending artery; PCI, percutaneous coronary intervention.
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complete. All-cause mortality was 24.9% in the proximal LAD
group (n=365) versus 26.3% in the nonproximal LAD group
(n=1114; P=0.60). MACE occurred less frequently in the
proximal LAD group: 24.6% versus 31.0% with a hazard ratio
of 0.77 (95% CI, 0.61–0.97; P=0.024). After multivariate
analysis, which included baseline characteristics that were
unevenly distributed between the groups, the hazard ratio for
MACE was 0.82 (95% CI, 0.65–1.03; P=0.09). As also noted in
the NOBLE (Nordic-Baltic-British Left Main Revascularization
Study) left main trial, a difference in outcomes may be driven
not by the lesion of interest (eg, left main or proximal LAD),
but by other de novo lesions.19
Limitations
The current study is a subgroup analysis of a prospective,
single-arm, multicenter observations Ultimaster DES registry
(e-Ultimaster), whichwas a postmarketing study aimed to assess
rates of TLF in all-comer patients treated with the thin-strut,
cobalt chromium, biodegradable-polymer, sirolimus-eluting coro-
nary stent Ultimaster in real-world situations.9 Our findings are
subject to certain limitations. First, our study is observational in
nature, and the stent strategy, stenting technique, and use of
adjuvant procedural techniques were based on operator choice,
rather than randomized as per in randomized controlled trials.
Second, only1 typeof stentwas used.Ourfindingsmay therefore
not be applicable to other stent platforms. Third, patients in the
proximal LAD group had worse baseline procedural and lesion
characteristics, and althoughweuseda robust statisticalmethod
to account for all the differences, the possibility of unmeasured
confounders cannot be ruled out. Fourth, the study outcomes
were clinically drivenwithdata aroundangiographic follow-up not
captured. Finally, while we observed similar outcomes at 1 year,
we cannot rule out significant differences in clinically relevant
end points in the longer term.
Conclusions
In this real-world analysis, we report good clinical safety and
procedural efficacy of a newer-generation thin-strut DES
(Ultimaster stent) in treating proximal LAD lesions compared
with other coronary lesions. Patients had comparable clinical
outcomes independent of stenting location and strategy.
Treatment of the proximal LAD with PCI did not confer a
different prognosis to lesion in different anatomical sites,
therefore questioning whether disease in the proximal LAD
should be regarded differently from that in other anatomical
sites within the coronary artery vasculature.
Sources of Funding
e-Ultimaster registry was funded by Terumo Europe. This
analysis of the registry was self-founded by the Department of
Cardiology of the Hillel Yaffe Medical Center & The Rappaport
School of Medicine, Technion-Israel Institute of Technology,
Hadera, Israel 3810808.
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Table S1. Segment information (per patient). 
Proximal LAD 
n=5452 
Non-proximal LAD 
n=12353 
p-value
1 RCA proximal 6.7 (366/5452) 17.5 (2164/12353) <0.001 
2 RCA mid 8.0 (434/5452) 22.2 (2739/12353) <0.001 
3 RCA distal 3.3 (182/5452) 10.2 (1257/12353) <0.001 
4 Posterior descending artery 0.9 (51/5452) 2.2 (270/12353) <0.001 
16 Posterolateral branch from RCA 0.8 (41/5452) 2.2 (265/12353) <0.001 
5 Left Main 0  (0/5452) 0% (0/12353) - 
6 LAD proximal 100 (5452/5452) 0% (0/12353) <0.001 
7 LAD mid 10.7 (585/5452) 32.2 (3973/12353) <0.001 
8 LAD apical 2.5 (136/5452) 3.0 (369/12353) 0.07 
9 First diagonal 4.3 (234/5452) 4.7 (581/12353) 0.24 
10 Second diagonal 0.2 (10/5452) 0.3 (31/12353) 0.50 
11 Proximal circumflex artery 7.4 (401/5452) 11.6 (1438/12353) <0.001 
12 Intermediate/anterolateral artery 2.4 (132/5452) 4.2 (516/12353) <0.001 
12a Obtuse marginal a 2.6 (144/5452) 5.8 (716/12353) <0.001 
12b Obtuse marginal b 0.4 (24/5452) 1.4 (169/12353) <0.001 
13 Distal circumflex artery 5.9 (323/5452) 12.6 (1556/12353) <0.001 
14 Left posterolateral 1.0 (52/5452) 2.2 (267/12353) <0.001 
15 Posterior descending 0.6 (30/5452) 1.4 (168/12353) <0.001 
LAD: left anterior descending artery; RCA: right coronary artery 
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Table S2. Unadjusted clinical outcomes. 
3-months 1-year
Proximal LAD 
n=5452 
Non-proximal 
LAD 
n=12353 
p-
value 
Proximal LAD 
n=5425 
Non-proximal 
LAD 
n=12353 
p-
value 
All-cause death 1.1 (58/5452) 0.8 (103/12353) 0.14 2.2 (120/5452) 2.0 (247/12353) 0.38 
Cardiac death 0.9 (47/5452) 0.6 (74/12353) 0.05 1.4 (74/5452) 1.2 (145/12353) 0.31 
Any MI 0.6 (30/5452) 0.7 (80/12353) 0.44 1.1 (57/5452) 1.1 (132/12353) 0.89 
Target-vessel MI 0.5 (27/5452) 0.5 (65/12353) 0.79 0.8 (45/5452) 0.8 (104/12353) 0.91 
All TLR 0.5 (27/5452) 0.4 (52/12353) 0.49 1.9 (104/5452) 1.3 (162/12353) 0.003 
Clinically driven TLR 0.5 (27/5452) 0.4 (52/12353) 0.67 1.8 (100/5452) 1.2 (153/12353) 0.002 
All TVR 0.6 (35/5452) 0.7 (80/12353) 0.97 2.5 (137/5452) 1.9 (239/12353) 0.01 
Clinically driven TVR 0.6 (32/5452) 0.6 (78/12353) 0.73 2.4 (130/5452) 1.8 (227/12353) 0.02 
TLF 1.5 (79/5452) 1.3 (155/12353) 0.29 3.4 (184/5452) 2.7 (337/12353) 0.02 
TVF 1.6 (85/5452) 1.4 (175/12353) 0.47 3.9 (210/5452) 3.2 (397/12353) 0.03 
POCE 2.4 (129/5452) 2.2 (277/12353) 0.61 6.1 (330/5452) 5.7 (704/12353) 0.35 
Definite or probable ST 0.5 (29/5452) 0.5 (61/12353) 0.74 0.7 (38/5452) 0.6 (71/12353) 0.34 
Bleeding (BARC 1-5) 1.3 (68/5452) 
1.3 (155/12353) 
0.97 2.2 (119/5452) 
2.2 
(266/12353) 
0.90 
Values are percentage (number) 
BARC: Bleeding Academic Research Consortium; MI: myocardial infarction; LAD: left 
anterior descending artery; POCE: patient-oriented composite endpoint, a composite of all-
cause death, any MI and any coronary revascularization; TLF: target lesion failure, a 
composite of cardiac death, target-vessel MI and clinically driven TLR; TLR: target lesion 
revascularization; TV: target vessel; TVF: target vessel failure, a composite of cardiac death, 
target-vessel MI and clinically driven TVR; TVR: target vessel revascularization; ST: stent 
thrombosis 
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Table S3. Clinical outcomes according to number of vessel diseased. 
1-year
Proximal LAD – 1 
vessel disease 
n=2776 
(%) 
Proximal LAD – 2 
vessels diseased 
n=1772 
(%) 
Proximal LAD – 3 
vessels diseased 
n=874 
(%) 
Overall 
p-value
All-cause death 1.69% (47/2,776) 1.92% (34/1,772) 4.24% (37/872) <0.001 
Cardiac death 0.94% (26/2,776) 1.19% (21/1,772) 2.87% (25/872) <0.001 
Any MI 0.58% (16/2,776) 0.96% (17/1,772) 2.64% (23/872) <0.001 
Target-vessel MI 0.50% (14/2,776) 0.73% (13/1,772) 2.06% (18/872) <0.001 
All TLR 1.59% (44/2,776) 1.75% (31/1,772) 3.33% (29/872) 0.004 
Clinically driven 
TLR 
1.51% (42/2,776) 1.64% (29/1,772) 3.33% (29/872) 0.002 
All TVR 1.95% (54/2,776) 2.77% (49/1,772) 3.90% (34/872) 0.004 
Clinically driven 
TVR 
1.87% (52/2,776) 2.48% (44/1,772) 3.90% (34/872) 0.003 
TLF 2.52% (70/2,776) 3.27% (58/1,772) 6.19% (54/872) <0.001 
TVF 2.85% (79/2,776) 4.01% (71/1,772) 6.65% (58/872) <0.001 
POCE 4.32% (120/2,776) 6.43% (114/1,772) 10.78% (94/872) <0.001 
Definite or 
probable ST 
0.58% (16/2,776) 0.51% (9/1,772) 1.49% (13/872) 0.009 
Bleeding (BARC 
1-5)
1.98% (55/2,776) 2.60% (46/1,772) 1.95% (17/872) 0.34 
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Table S4. Clinical outcomes according to diabetes. 
1-year outcomes
Proximal LAD – Diabetes 
n=1457 
Proximal LAD – No diabetes 
n=3995 
p-value
All-cause death 3.16% (46/1,457) 1.85% (74/3,995) 0.004 
Cardiac death 2.13% (31/1,457) 1.08% (43/3,995) 0.003 
Any MI 1.37% (20/1,457) 0.93% (37/3,995) 0.15 
Target-vessel MI 1.17% (17/1,457) 0.70% (28/3,995) 0.09 
All TLR 2.95% (43/1,457) 1.53% (61/3,995) <0.001 
Clinically driven 
TLR 
2.95% (43/1,457) 1.43% (57/3,995) <0.001 
All TVR 3.71% (54/1,457) 2.08% (83/3,995) <0.001 
Clinically driven 
TVR 
3.71% (54/1,457) 1.90% (76/3,995) <0.001 
TLF 5.35% (78/1,457) 2.65% (106/3,995) <0.001 
TVF 5.97% (87/1,457) 3.08% (123/3,995) <0.001 
POCE 8.30% (121/1,457) 5.23% (209/3,995) <0.001 
Definite or 
probable ST 
0.82% (12/1,457) 0.65% (26/3,995) 0.50 
Bleeding (BARC 
1-5)
1.99% (29/1,457) 2.25% (90/3,995) 0.56 
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Standardized difference for all variables below 0.20 are considered well balanced, 
while standardized difference for all variables below 0.10 can be considered 
extremely well balanced (STEMI: ST-elevation myocardial infarction; PCI: 
percutaneous Coronary intervention. 
Figure S1. Standardized differences in variables included in the propensity score between 
proximal LAD versus non-proximal LAD group. 
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Figure S2. Comparison between 1 or 2 vessel disease vs 3 vessels diseased. 
Multivessel disease was not a significant effect modifier for the risk of TLF between 
proximal LAD and non-proximal LAD group (no significant interaction effect) 
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Figure S3. Comparison between diabetes and non-diabetes in Proximal LAD group. 
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